Go Pro
→ Sell Tesla, Buy the New King of FSD Cars (From Chaikin Analytics) (Ad)tc pixel Free PMN Stock Alerts

Promis Neurosciences (PMN) Financials

Promis Neurosciences logo
$14.25 -0.02 (-0.14%)
Closing price 04:00 PM Eastern
Extended Trading
$14.04 -0.22 (-1.51%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Promis Neurosciences

Annual Income Statements for Promis Neurosciences

This table shows Promis Neurosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2021 2022 2023 2024 2025
Period end date 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -9.79 -18 -13 2.78 -40
Consolidated Net Income / (Loss)		 -9.79 -18 -13 2.78 -40
Net Income / (Loss) Continuing Operations		 -9.79 -18 -13 2.78 -40
Total Pre-Tax Income 		-9.79 -18 -14 2.78 -40
Total Operating Income		 -8.29 -23 -14 -17 -40
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 8.29 23 14 17 40
Selling, General & Admin Expense		 3.66 7.29 6.38 6.19 6.79
Research & Development Expense		 4.63 16 7.88 11 33
Total Other Income / (Expense), net		 -1.50 5.32 0.67 20 0.45
Interest Expense		 0.42 0.28 0.20 0.08 0.00
Other Income / (Expense), net		 -1.08 5.60 0.87 20 0.44
Basic Earnings per Share		 ($1.69) ($2.41) ($1.07) $2.68 ($22.61)
Weighted Average Basic Shares Outstanding		 5.79M 7.50M 12.29M 1.04M 1.76M
Diluted Earnings per Share		 ($1.69) ($2.41) ($1.07) $2.63 ($22.61)
Weighted Average Diluted Shares Outstanding		 5.79M 7.50M 12.29M 1.06M 1.76M
Weighted Average Basic & Diluted Shares Outstanding		 - 8.58M 18.96M 32.69M 8.97M

Quarterly Income Statements for Promis Neurosciences

This table shows Promis Neurosciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -2.36 -3.41 -3.64 -2.62 9.28 -0.24 -7.35 -10 -12 -11 -8.24
Consolidated Net Income / (Loss)		 -2.36 -3.58 -3.64 -2.62 9.28 -0.24 -7.35 -10 -12 -11 -8.24
Net Income / (Loss) Continuing Operations		 -2.36 -3.62 -3.64 -2.62 9.28 -0.24 -7.35 -10 -12 -11 -8.24
Total Pre-Tax Income 		-2.36 -4.01 -3.64 -2.62 9.28 -0.24 -7.35 -10 -12 -11 -8.24
Total Operating Income		 -2.52 -3.87 -3.68 -2.71 -4.43 -6.00 -7.46 -10 -12 -11 -8.64
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 2.52 3.87 3.68 2.71 4.43 6.00 7.46 10 12 11 8.64
Selling, General & Admin Expense		 1.38 1.65 1.55 1.09 1.87 1.68 2.00 1.43 1.95 1.40 1.67
Research & Development Expense		 1.14 2.23 2.12 1.63 2.56 4.32 5.46 8.75 9.80 9.37 6.97
Total Other Income / (Expense), net		 0.16 -0.13 0.04 0.09 14 5.76 0.11 0.07 0.17 0.10 0.40
Other Income / (Expense), net		 0.23 -0.06 0.12 0.09 14 5.76 0.11 0.07 0.17 0.09 0.40
Basic Earnings per Share		 ($0.19) ($0.03) ($0.19) ($0.13) $0.31 ($0.23) ($5.27) ($0.29) ($0.24) ($6.08) ($1.26)
Weighted Average Basic Shares Outstanding		 12.37M 12.29M 19.53M 19.77M 30.02M 1.04M 1.39M 34.85M 48.83M 1.76M 6.53M
Diluted Earnings per Share		 ($0.19) ($0.03) ($0.19) ($0.13) $0.31 ($0.23) ($5.27) ($0.29) ($0.24) ($6.08) ($1.26)
Weighted Average Diluted Shares Outstanding		 12.37M 12.29M 19.53M 19.77M 30.07M 1.06M 1.39M 34.85M 48.83M 1.76M 6.53M
Weighted Average Basic & Diluted Shares Outstanding		 - 18.96M 18.96M 29.89M 32.69M 32.69M 32.69M 51.81M 53.81M 8.97M 8.97M

Annual Cash Flow Statements for Promis Neurosciences

This table details how cash moves in and out of Promis Neurosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2021 2022 2023 2024 2025
Period end date 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 16 -11 6.72 0.69 -7.17
Net Cash From Operating Activities		 -9.31 -17 -11 -27 -28
Net Cash From Continuing Operating Activities		 -9.31 -17 -11 -27 -28
Net Income / (Loss) Continuing Operations		 -9.79 -18 -13 2.78 -40
Consolidated Net Income / (Loss)		 -9.79 -18 -13 2.78 -40
Non-Cash Adjustments To Reconcile Net Income		 -0.30 -2.08 0.27 4.35 0.86
Changes in Operating Assets and Liabilities, net		 0.37 2.85 2.08 -34 11
Net Cash From Investing Activities		 0.09 -0.00 -0.00 -0.00 -0.00
Net Cash From Continuing Investing Activities		 0.09 -0.00 -0.00 -0.00 -0.00
Purchase of Investments		 -0.03 -0.03 -0.03 -0.03 -0.03
Sale and/or Maturity of Investments		 0.03 0.03 0.03 0.03 0.03
Net Cash From Financing Activities		 26 6.49 18 28 21
Net Cash From Continuing Financing Activities		 26 6.49 18 28 21
Issuance of Debt		 6.92 - - 0.00 0.70
Issuance of Common Equity		 19 6.49 18 28 20
Other Financing Activities, net		 - 0.00 0.00 0.03 0.00
Cash Interest Paid		 0.00 0.09 0.20 0.08 0.00

Quarterly Cash Flow Statements for Promis Neurosciences

This table details how cash moves in and out of Promis Neurosciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 16 -4.27 -10 -1.50 21 -8.25 -4.93 -3.85 11 -9.28 58
Net Cash From Operating Activities		 -2.38 -3.76 -10 -1.50 -6.67 -8.72 -4.93 -3.85 -10 -9.28 -12
Net Cash From Continuing Operating Activities		 -2.38 -3.76 -10 -1.50 -6.67 -8.72 -4.93 -3.85 -10 -9.28 -12
Net Income / (Loss) Continuing Operations		 -2.36 -3.58 -3.64 -2.62 9.28 -0.24 -7.35 -10 -12 -11 -8.24
Consolidated Net Income / (Loss)		 -2.36 -3.58 -3.64 -2.62 9.28 -0.24 -7.35 -10 -12 -11 -8.24
Non-Cash Adjustments To Reconcile Net Income		 0.61 0.01 0.08 -0.04 3.66 0.65 0.25 0.21 0.20 0.20 0.19
Changes in Operating Assets and Liabilities, net		 -0.62 -0.20 -6.73 1.16 -20 -9.13 2.18 6.05 1.33 1.19 -4.33
Net Cash From Investing Activities		 - -0.00 0.00 - - -0.00 0.00 - - -0.00 0.00
Net Cash From Continuing Investing Activities		 - -0.00 0.00 - - -0.00 0.00 - - -0.00 0.00
Net Cash From Financing Activities		 18 -0.51 0.19 - 27 0.47 0.00 - 21 -0.00 70
Net Cash From Continuing Financing Activities		 18 -0.51 0.19 - 27 0.47 0.00 - 21 -0.00 70
Issuance of Common Equity		 18 -0.51 0.19 - 27 0.47 0.00 - 20 -0.00 70

Annual Balance Sheets for Promis Neurosciences

This table presents Promis Neurosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2021 2022 2023 2024 2025
Period end date 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 18 6.92 14 19 9.18
Total Current Assets		 18 6.90 14 19 9.18
Cash & Equivalents		 17 5.88 13 13 6.12
Short-Term Investments		 0.03 0.03 0.03 0.03 0.03
Prepaid Expenses		 0.74 1.00 0.99 5.59 3.03
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.03 0.02 0.00 0.00 0.00
Other Noncurrent Operating Assets		 - - - - 0.00
Total Liabilities & Shareholders' Equity		 18 6.92 14 19 9.18
Total Liabilities		 12 8.27 9.87 2.42 10
Total Current Liabilities		 0.93 6.41 9.35 2.22 10
Accounts Payable		 0.41 2.98 7.84 1.74 2.54
Accrued Expenses		 0.52 3.44 1.51 0.48 7.87
Total Noncurrent Liabilities		 11 1.86 0.52 0.20 0.03
Noncurrent Employee Benefit Liabilities		 - 0.00 0.42 0.20 0.03
Total Equity & Noncontrolling Interests		 5.66 -1.35 3.75 16 -1.26
Total Preferred & Common Equity		 5.66 -1.35 3.75 16 -1.26
Total Common Equity		 5.66 -1.35 3.75 16 -1.26
Common Stock		 68 79 98 108 130
Retained Earnings		 -62 -80 -93 -91 -130
Accumulated Other Comprehensive Income / (Loss)		 -0.19 -0.20 -0.37 -0.37 -0.37

Quarterly Balance Sheets for Promis Neurosciences

This table presents Promis Neurosciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 3.55 1.41 25 14 9.51 21 67
Total Current Assets		 3.55 1.41 25 14 9.51 21 66
Cash & Equivalents		 2.50 0.99 22 8.36 4.51 15 64
Short-Term Investments		 0.03 0.03 0.03 0.03 0.03 0.03 0.03
Prepaid Expenses		 1.02 0.38 2.94 5.25 4.97 6.03 1.76
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.00 0.00 0.00 0.00 0.00 0.00 1.80
Other Noncurrent Operating Assets		 - - - - - - 1.80
Total Liabilities & Shareholders' Equity		 3.55 1.41 25 14 9.51 21 67
Total Liabilities		 3.47 3.69 17 4.17 9.89 12 6.69
Total Current Liabilities		 2.65 3.17 2.64 4.06 9.82 12 6.61
Accounts Payable		 1.40 2.02 1.58 1.20 2.78 4.21 1.72
Accrued Expenses		 1.24 1.16 1.06 2.86 7.04 8.00 4.90
Total Noncurrent Liabilities		 0.83 0.51 15 0.12 0.07 0.06 0.08
Noncurrent Employee Benefit Liabilities		 0.72 0.47 0.34 0.11 0.06 0.05 0.08
Total Equity & Noncontrolling Interests		 0.08 -2.28 7.27 9.47 -0.38 9.19 61
Total Preferred & Common Equity		 0.08 -2.28 7.27 9.47 -0.38 9.19 61
Total Common Equity		 0.08 -2.28 7.27 9.47 -0.38 9.19 61
Common Stock		 98 98 98 108 108 129 200
Retained Earnings		 -97 -100 -90 -98 -108 -120 -139
Accumulated Other Comprehensive Income / (Loss)		 -0.37 -0.37 -0.37 -0.37 -0.37 -0.37 -0.37

Annual Metrics And Ratios for Promis Neurosciences

This table displays calculated financial ratios and metrics derived from Promis Neurosciences' official financial filings.

Metric 2021 2022 2023 2024 2025
Period end date 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 8,579,284.00 8,579,284.00 32,689,190.00 53,811,110.00
DEI Adjusted Shares Outstanding		 0.00 343,171.00 343,171.00 1,307,568.00 2,152,444.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -52.63 -38.50 2.13 -18.45
Growth Metrics		 - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -95.57% 23.69% 121.35% -1,491.09%
EBIT Growth		 0.00% -89.68% 24.66% 121.32% -1,491.09%
NOPAT Growth		 0.00% -181.99% 39.00% -68.55% -67.09%
Net Income Growth		 0.00% -84.50% 26.85% 121.03% -1,529.33%
EPS Growth		 0.00% -42.60% 55.60% 121.03% -959.70%
Operating Cash Flow Growth		 0.00% -83.05% 36.34% -150.67% -3.45%
Free Cash Flow Firm Growth		 0.00% 0.00% 49.39% -245.27% 39.23%
Invested Capital Growth		 0.00% 2.11% -22.37% 135.64% -334.17%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 20.06% 441.44% -35.66%
EBIT Q/Q Growth		 0.00% 0.00% 19.93% 441.44% -35.66%
NOPAT Q/Q Growth		 0.00% 0.00% 24.58% -63.54% -13.47%
Net Income Q/Q Growth		 0.00% 0.00% 21.81% 593.28% -35.64%
EPS Q/Q Growth		 0.00% 0.00% 44.56% 593.28% -3,546.77%
Operating Cash Flow Q/Q Growth		 0.00% -3.07% 6.83% -22.30% -2.06%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -820.59% 46.56%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 122.13% -18.64%
Profitability Metrics		 - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 97.17% 100.00% 99.99%
Interest Burden Percent		 104.44% 101.59% 101.50% 97.31% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -172.97% -837.71% -1,098.51% 27.46% -521.61%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% -912.42% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -172.97% -837.71% -1,098.51% 27.46% -521.61%
Return on Equity Simple (ROE_SIMPLE)		 -172.97% 1,340.16% -352.02% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -5.80 -16 -9.98 -17 -28
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -30.50% -17.88% -34.83% 151.08% -119.15%
Return On Investment Capital (ROIC_SIMPLE)		 - - -266.00% -102.06% 2,234.01%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -9.37 -18 -13 2.86 -40
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -8.96 -18 -13 2.86 -40
Valuation Ratios		 - - - - -
Price to Book Value (P/BV)		 0.00 0.00 2.63 1.88 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 2.63 1.88 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 11.15 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 8.97% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 5.58 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 6.18 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 6.18 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - -
Debt to Equity		 0.69 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.69 0.00 0.00 0.00 0.00
Financial Leverage		 -2.31 -4.40 -7.71 -1.28 -1.28
Leverage Ratio		 3.14 5.72 8.54 1.61 1.84
Compound Leverage Factor		 3.27 5.81 8.67 1.56 1.84
Debt to Total Capital		 40.83% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 40.83% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 59.17% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 -0.44 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 1.46 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 -0.44 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.67 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 2.25 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 -0.67 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 -21.91 -11.88 2.52 -33.48
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - -
Current Ratio		 19.07 1.08 1.46 8.52 0.88
Quick Ratio		 18.27 0.92 1.35 6.01 0.59
Cash Flow Metrics		 - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -17 -8.36 -29 -18
Operating Cash Flow to CapEx		 0.00% -859,862.85% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 -58.58 -41.52 -376.02 0.00
Operating Cash Flow to Interest Expense		 -22.35 -60.39 -53.84 -354.05 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -22.13 -60.40 -53.84 -354.05 0.00
Efficiency Ratios		 - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - -
Invested Capital		 -7.41 -7.25 -8.88 3.16 -7.41
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 0.16 -1.62 12 -11
Enterprise Value (EV)		 0.00 31 -2.76 18 8.54
Market Capitalization		 0.00 37 9.87 31 15
Book Value per Share		 $0.98 ($0.16) $0.44 $0.50 ($0.02)
Tangible Book Value per Share		 $0.97 ($0.16) $0.44 $0.50 ($0.02)
Total Capital		 9.57 -1.35 3.75 16 -1.26
Total Debt		 3.91 0.00 0.00 0.00 0.00
Total Long-Term Debt		 3.91 0.00 0.00 0.00 0.00
Net Debt		 -13 -5.91 -13 -13 -6.15
Capital Expenditures (CapEx)		 -0.09 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.19 -5.42 -8.36 3.37 -7.38
Debt-free Net Working Capital (DFNWC)		 17 0.49 4.27 17 -1.23
Net Working Capital (NWC)		 17 0.49 4.27 17 -1.23
Net Nonoperating Expense (NNE)		 3.99 1.70 3.23 -20 12
Net Nonoperating Obligations (NNO)		 -13 -5.91 -13 -13 -6.15
Total Depreciation and Amortization (D&A)		 0.41 0.25 0.02 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($2.41) ($1.07) $2.75 ($22.61)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 7.50M 12.29M 1.04M 1.76M
Adjusted Diluted Earnings per Share		 $0.00 ($2.41) ($1.07) $2.75 ($22.61)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 7.50M 12.29M 1.06M 1.76M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 8.58M 18.96M 1.31M 8.97M
Normalized Net Operating Profit after Tax (NOPAT)		 -5.80 -16 -9.98 -12 -28
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - -
EBIT to Interest Expense		 -22.52 -63.04 -66.52 37.20 0.00
NOPAT to Interest Expense		 -13.94 -58.02 -49.58 -219.18 0.00
EBIT Less CapEx to Interest Expense		 -22.30 -63.04 -66.52 37.20 0.00
NOPAT Less CapEx to Interest Expense		 -13.72 -58.03 -49.58 -219.18 0.00
Payout Ratios		 - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Promis Neurosciences

This table displays calculated financial ratios and metrics derived from Promis Neurosciences' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 8,579,284.00 8,579,284.00 18,961,116.00 18,961,116.00 29,885,452.00 32,689,190.00 32,689,190.00 32,689,190.00 51,806,497.00 53,811,110.00 8,967,693.00
DEI Adjusted Shares Outstanding		 343,171.00 343,171.00 758,445.00 758,445.00 1,195,418.00 1,307,568.00 1,307,568.00 1,307,568.00 2,072,260.00 2,152,444.00 8,967,693.00
DEI Earnings Per Adjusted Shares Outstanding		 -6.88 -9.93 -4.79 -3.46 7.76 -0.18 -5.62 -7.74 -5.59 -4.96 -0.92
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 61.64% 46.18% 27.62% -16.01% 505.96% 93.91% -106.50% -285.61% -224.84% -4,383.36% -12.20%
EBIT Growth		 61.64% 45.91% 27.64% -15.95% 505.90% 93.94% -106.50% -285.61% -224.84% -4,383.36% -12.20%
NOPAT Growth		 58.42% 54.54% 26.03% 6.42% -151.64% -54.92% -102.90% -275.30% -85.48% -79.46% -15.88%
Net Income Growth		 60.37% 50.72% 26.70% -13.48% 492.94% 93.35% -102.14% -285.61% -224.84% -4,381.01% -12.20%
EPS Growth		 77.65% 96.63% 67.24% 51.85% 263.16% 93.35% -102.14% -123.08% -177.42% -2,543.48% 76.09%
Operating Cash Flow Growth		 48.74% 17.47% -301.75% 29.94% -180.72% -131.89% 52.13% -156.18% -50.73% -6.50% -151.35%
Free Cash Flow Firm Growth		 -390.35% 0.00% -259.40% -251.65% 297.87% -1,390.70% 9.47% 34.31% -265.05% 118.67% 78.89%
Invested Capital Growth		 0.00% -22.37% 74.30% 66.25% 0.00% 135.64% 143.81% -49.18% 56.32% -334.17% -391.38%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -1.03% -71.22% 9.05% 26.27% 453.55% -102.57% -2,984.67% -37.69% -14.46% 7.78% 22.80%
EBIT Q/Q Growth		 -0.99% -71.98% 9.46% 26.27% 453.55% -102.57% -2,984.67% -37.69% -14.46% 7.78% 22.80%
NOPAT Q/Q Growth		 13.18% -53.91% 5.11% 26.19% -133.45% 5.25% -24.28% -36.52% -15.37% 8.33% 19.75%
Net Income Q/Q Growth		 -2.11% -51.67% -1.53% 27.82% 453.55% -102.57% -2,984.67% -37.69% -14.46% 7.82% 22.76%
EPS Q/Q Growth		 29.63% 84.21% -533.33% 31.58% 338.46% -102.57% -2,984.67% -38.10% 17.24% -2,433.33% 79.28%
Operating Cash Flow Q/Q Growth		 -10.67% -58.14% -173.84% 85.38% -343.41% -30.64% 43.47% 21.77% -160.90% 7.69% -33.42%
Free Cash Flow Firm Q/Q Growth		 -190.18% 78.14% -786.86% 13.28% 217.67% -264.71% 46.14% 37.07% -195.64% 118.63% -160.89%
Invested Capital Q/Q Growth		 100.00% 0.00% 72.38% -34.65% -332.96% 122.13% -66.04% -558.47% -26.78% -18.64% 57.75%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 89.35% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 99.95% 100.00%
Interest Burden Percent		 103.30% 101.95% 102.16% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -1,098.51% 389.65% 225.81% -7.75% 27.46% -19.56% 633.71% -355.80% -521.61% -115.73%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% -912.42% -1,671.13% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.00% -1,098.51% 389.65% 225.81% -7.75% 27.46% -19.56% 633.71% -355.80% -521.61% -115.73%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -1.76 -2.71 -2.57 -1.90 -4.43 -4.20 -5.22 -7.13 -8.23 -7.54 -6.05
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.00% -9.37% -36.03% -63.53% 127.13% 30.54% -38.91% -107.32% -18.13% -32.18% -6.07%
Return On Investment Capital (ROIC_SIMPLE)		 - -72.26% -3,338.12% 83.42% -60.97% -25.48% -55.13% 1,863.48% -89.53% 599.12% -9.97%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -2.29 -3.93 -3.56 -2.62 9.28 -0.24 -7.35 -10 -12 -11 -8.24
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -2.28 -3.91 -3.56 -2.62 9.28 -0.24 -7.35 -10 -12 -11 -8.24
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 2.63 212.54 0.00 5.14 1.88 2.40 0.00 2.40 0.00 1.88
Price to Tangible Book Value (P/TBV)		 0.00 2.63 212.54 0.00 5.14 1.88 2.40 0.00 2.40 0.00 1.88
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 11.15 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 8.97% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 5.58 13.35 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 6.18 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 6.18 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 3.94 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 -7.71 0.97 0.21 -2.97 -1.28 -1.14 2.09 -2.25 -1.28 -1.03
Leverage Ratio		 0.00 8.54 -1.31 -0.27 3.37 1.61 1.80 -4.11 2.79 1.84 1.15
Compound Leverage Factor		 0.00 8.71 -1.34 -0.27 3.37 1.61 1.80 -4.11 2.79 1.84 1.15
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 -9.58 -38.48 -102.06 -1.55 1.98 -7.72 -18.51 -8.00 -23.04 7.98
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.00 1.46 1.34 0.44 9.30 8.52 3.36 0.97 1.76 0.88 9.92
Quick Ratio		 0.00 1.35 0.96 0.32 8.19 6.01 2.07 0.46 1.26 0.59 9.65
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -4.98 -1.09 -9.66 -8.38 9.86 -16 -8.75 -5.51 -16 3.03 -1.85
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -66.09 -14.19 -125.87 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -31.51 -48.94 -134.05 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -31.51 -48.94 -134.05 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.00 -8.88 -2.45 -3.30 -14 3.16 1.07 -4.93 -6.24 -7.41 -3.13
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 3.22 -1.62 7.09 6.48 -14 12 3.53 -1.62 8.05 -11 -4.20
Enterprise Value (EV)		 0.00 -2.76 14 27 16 18 14 11 6.59 8.54 50
Market Capitalization		 17 9.87 16 28 37 31 23 16 22 15 114
Book Value per Share		 $0.00 $0.44 $0.01 ($0.12) $0.24 $0.50 $0.29 ($0.01) $0.18 ($0.02) $6.77
Tangible Book Value per Share		 $0.00 $0.44 $0.01 ($0.12) $0.24 $0.50 $0.29 ($0.01) $0.18 ($0.02) $6.77
Total Capital		 0.00 3.75 0.08 -2.28 7.27 16 9.47 -0.38 9.19 -1.26 61
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 -13 -2.53 -1.02 -22 -13 -8.40 -4.54 -15 -6.15 -64
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -8.36 -1.63 -2.79 0.31 3.37 1.19 -4.86 -6.19 -7.38 -4.85
Debt-free Net Working Capital (DFNWC)		 0.00 4.27 0.90 -1.76 22 17 9.59 -0.31 9.25 -1.23 59
Net Working Capital (NWC)		 0.00 4.27 0.90 -1.76 22 17 9.59 -0.31 9.25 -1.23 59
Net Nonoperating Expense (NNE)		 0.60 0.87 1.06 0.72 -14 -3.96 2.13 2.99 3.35 3.13 2.19
Net Nonoperating Obligations (NNO)		 0.00 -13 -2.53 -1.02 -22 -13 -8.40 -4.54 -15 -6.15 -64
Total Depreciation and Amortization (D&A)		 0.00 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($0.03) ($0.19) ($0.13) $0.31 ($5.75) ($5.25) ($0.29) ($0.24) ($6.08) ($1.26)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 12.29M 19.53M 19.77M 30.02M 41.47K 1.39M 34.85M 48.83M 1.76M 6.53M
Adjusted Diluted Earnings per Share		 $0.00 ($0.03) ($0.19) ($0.13) $0.31 ($5.75) ($5.25) ($0.29) ($0.24) ($6.08) ($1.26)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 12.29M 19.53M 19.77M 30.07M 42.34K 1.39M 34.85M 48.83M 1.76M 6.53M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 ($5.75) $0.00 $0.00 $0.00 ($6.08) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 18.96M 18.96M 29.89M 32.69M 1.31M 1.31M 51.81M 53.81M 8.97M 8.97M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.76 -2.71 -2.57 -1.90 -3.10 -4.20 -5.22 -7.13 -8.23 -7.54 -6.05
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -30.30 -51.18 -46.35 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -23.37 -35.32 -33.52 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -30.30 -51.18 -46.35 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -23.37 -35.32 -33.52 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Promis Neurosciences Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Promis Neurosciences' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Promis Neurosciences' net income appears to be on an upward trend, with a most recent value of -$39.72 million in 2025, rising from -$9.79 million in 2021. The previous period was $2.78 million in 2024. Check out Promis Neurosciences' forecast to explore projected trends and price targets.

Promis Neurosciences' total operating income in 2025 was -$40.17 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $40.17 million

Over the last 4 years, Promis Neurosciences' total revenue changed from $0.00 in 2021 to $0.00 in 2025, a change of 0.0%.

Promis Neurosciences' total liabilities were at $10.44 million at the end of 2025, a 330.9% increase from 2024, and a 13.6% decrease since 2021.

In the past 4 years, Promis Neurosciences' cash and equivalents has ranged from $5.88 million in 2022 to $16.94 million in 2021, and is currently $6.12 million as of their latest financial filing in 2025.

Over the last 4 years, Promis Neurosciences' book value per share changed from 0.98 in 2021 to -0.02 in 2025, a change of -102.4%.


Related Companies

Financial statements for NASDAQ:PMN last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
Is the fix for AI's runaway power problem your golden ticket?
The government just committed $200 billion to building computer chips on American soil - one of the largest te...
Eagle Publishing | Sponsoredtc pixel
Ray Dalio: Buy Gold. Get Paid.
Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...
Investors Alley | Sponsoredtc pixel
A better retirement stock than Berkshire?
Whitney Tilson - the analyst CNBC called 'The Prophet' for early calls on Netflix, Apple, and Amazon - says he...
Stansberry Research | Sponsoredtc pixel
Executive order could send gold to 6,000 per ounce
Executive Order 14330 will allow Americans to hold precious metals inside 401(k)s for the first time ever - an...
Cedar Gold Group | Sponsoredtc pixel
Your withdrawal order could cost you in taxes
If you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...
SmartAsset | Sponsoredtc pixel